- Home
- WLAC vs SXTC Comparison
WLAC vs SXTC Comparison
Compare WLAC & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
HOLD
Current Price
$0.15
Company Overview
Basic Information| Metric | WLAC | SXTC |
|---|---|---|
| Founded | 2024 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 177.7M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WLAC | SXTC |
|---|---|---|
| Price | $12.80 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 224.9K | ★ 5.5M |
| Earning Date | 01-01-0001 | 08-19-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,537,987.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $902.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.89 | $0.95 |
| 52 Week High | $15.19 | $7.84 |
Technical Indicators
Market Signals| Indicator | WLAC | SXTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 24.19 |
| Support Level | $12.30 | $1.61 |
| Resistance Level | $13.65 | $6.98 |
| Average True Range (ATR) | 0.58 | 0.62 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 54.00 | 0.12 |
Price Performance
Historical Comparison WLAC
SXTC
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.